Impact of Coronavirus Disease 2019 on Time Delay and Functional Outcome of Mechanical Thrombectomy in Tokyo, Japan.
Acute ischemic stroke
COVID-19
Epidemiology
Thrombectomy
Journal
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
07
06
2021
revised:
04
08
2021
accepted:
08
08
2021
pubmed:
23
8
2021
medline:
14
10
2021
entrez:
22
8
2021
Statut:
ppublish
Résumé
An association has been reported between delays in the onset-to-door (O2D) time for mechanical thrombectomy (MT) and outbreaks of coronavirus disease 2019 (COVID-19). However, the association between other MT time courses or functional outcomes and COVID-19 outbreaks remains unclear. We compared the time courses of stroke pathways or functional outcomes in 2020 (the COVID-19 era) with those in 2019 (the pre-COVID-19 era) in Tokyo, Japan. This retrospective observational study used data from the Tokyo-tama-REgistry of Acute endovascular Thrombectomy (TREAT), a multicenter registry of MT for acute large vessel occlusion in the Tokyo Metropolitan Area. Patients who had undergone acute MT from January 2019 to December 2020 were included. Patients were classified by the year they had undergone MT (2019 or 2020). In total, 477 patients were analyzed. O2D time was significantly longer in 2020 (146.0 min) than in 2019 (105.0 min; p = 0.034). No significant difference in door-to-puncture time (D2P) time or modified Rankin Scale (mRS) score 0-2 at 90 days was seen between 2019 and 2020. In the subgroup analysis, O2D time was significantly longer in the first half of 2020 compared with 2019. Multivariable logistic regression analysis revealed that the year 2020 was a independent predictor of longer O2D time, but not for mRS score 0-2 at 90 days. Although O2D time was significantly longer in the COVID-19 compared with the pre-COVID-19 era, D2P may not be significantly delayed and functional outcomes may not be different, despite the COVID-19 pandemic.
Identifiants
pubmed: 34419835
pii: S1052-3057(21)00456-0
doi: 10.1016/j.jstrokecerebrovasdis.2021.106051
pmc: PMC8361142
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
106051Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Yoshiaki Shiokawa has received research grants from AbbVie GK and ONO Pharmaceitocal CO., LTD. Teruyuki Hirano has received honoraria from Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Otsuka Pharma, Pfizer, and Sanofi. All the other authors have nothing to disclosure.
Références
Stroke. 2017 Nov;48(11):3049-3056
pubmed: 28974631
J Neurointerv Surg. 2020 Jul;12(7):664-668
pubmed: 32451358
Stroke. 2020 Jul;51(7):2228-2231
pubmed: 32432998
J Stroke Cerebrovasc Dis. 2017 Nov;26(11):2477-2481
pubmed: 28935501
J Neurointerv Surg. 2020 Jul;12(7):639-642
pubmed: 32467244
Front Neurol. 2020 Nov 30;11:601652
pubmed: 33424751
N Engl J Med. 2020 May 14;382(20):e60
pubmed: 32343504
PLoS One. 2021 Mar 25;16(3):e0247829
pubmed: 33765030
Stroke. 2020 Nov;51(11):3366-3370
pubmed: 32813602
J Stroke Cerebrovasc Dis. 2018 Nov;27(11):3350-3355
pubmed: 30154049
Int J Stroke. 2021 Jul;16(5):573-584
pubmed: 33459583
Front Neurol. 2020 Sep 04;11:907
pubmed: 33013629
Intern Med J. 2019 Mar;49(3):345-351
pubmed: 30091271
Eur J Neurol. 2020 Sep;27(9):1788-1792
pubmed: 32415888
J Stroke Cerebrovasc Dis. 2020 Dec;29(12):105271
pubmed: 32992192
Neurocrit Care. 2018 Dec;29(3):426-434
pubmed: 29946761
BMC Neurol. 2020 Mar 5;20(1):81
pubmed: 32138684
Stroke. 2013 Sep;44(9):2650-63
pubmed: 23920012